AnGes (AMGXF) Financial Strength: 0 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMGXF AnGes Inc AMGXF
41 GF Score
Price $0.36
GF Value $0.45
! 4 Warning Signs
View Full Analysis

What is AnGes Financial Strength?

AnGes has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

GuruFocus does not calculate AnGes's interest coverage with the available data. As of today, AnGes's Altman Z-Score is -20.07.


AnGes  (OTCPK:AMGXF) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

AnGes has the Financial Strength Rank of 0.


AnGes Financial Strength Related Terms


AMGXF vs VRTX, REGN, RVMD: Financial Strength Comparison

For the Biotechnology subindustry, AnGes's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AnGes Financial Strength vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnGes's Financial Strength distribution charts can be found below:

* The bar in red indicates where AnGes's Financial Strength falls into.


AMGXF
41GF Score
AnGes Inc AMGXF
Financial Strength is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AnGes Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

AnGes's Interest Expense for the months ended in Jun. 2026 was $0.00 Mil. Its Operating Income for the months ended in Jun. 2026 was $0.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $3.82 Mil.

AnGes's Interest Coverage for the quarter that ended in Jun. 2026 is

GuruFocus does not calculate AnGes's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

AnGes's Debt to Revenue Ratio for the quarter that ended in Jun. 2026 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2026 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.679 + 3.823) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

AnGes has a Z-score of -20.07, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -20.07 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is AnGes (AMGXF) Overvalued in 2026?

Based on GuruFocus' analysis, AnGes stock appears to be undervalued. The current stock price of $0.36 is trading 20% below its estimated GF Value™ of $0.45.

Key valuation signals for AMGXF:

  • Financial Strength: 0
  • GF Value™: $0.45 vs. price of $0.36 (20% below fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the AMGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AnGes Business Description

Other Exchanges 4563:JapanAJW:Germany
Address 7-7-15, Saito-asagi, 4F, Saito Bio-Incubator, Ibaraki, Osaka, JPN, 567-0085
AnGes Inc is a biopharmaceutical company. The company is involved in research and development and sales of pharmaceuticals such as gene-based drugs (gene therapy products, nucleic acid drugs); contract testing for rare genetic diseases, etc.
41GF Score

Get the complete analysis for AMGXF

Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.36
Price
$0.45
GF Value